Terms ending in 2038
Every in-force patent on AstraZeneca AB's record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,961,228 | JAK1 Selective Inhibitors In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 11,897,869 | JAK1 Selective Inhibitors In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 12,473,272 | JAK1 Selective Inhibitors In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 10,221,173 | Chemical Compounds In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 10,590,132 | Selective Estrogen Receptor Down-Regulators In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 11,046,689 | Selective Estrogen Receptor Down-Regulators In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 10,314,920 | Therapeutic Dendrimers In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 10,888,624 | Therapeutic Dendrimers In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 11,717,574 | Therapeutic Dendrimers In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 10,273,227 | C5-ANILINOQUINAZOLINE Compounds and Their Use in Treating Cancer In force · High confidence | AstraZeneca AB | In force | High confidence | |
| 13 more term ends in 2038 · Pro | |||||
10 of 23 patents shown. Soonest term end first, then patent number.
Pro members see all 23.
22 of these are in force and held by AstraZeneca AB.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.